1. Scrip
  2. >>Business

As Its Debut Cancer Drug Struggles, MorphoSys Continues Refocus With $1bn Licensing Deal

Two Assets Outlicensed

 
• By Andrew McConaghie

The deal will help MorphoSys focus on lifting lackluster Monjuvi sales, and on bringing its promising myelofibrosis candidate pelabresib to market.

MorphoSys
The outlicensing deal will free up MorphoSys' internal resources to focus on key pipeline assets, starting with pelabresib. • Source: Shutterstock

Struggling with underwhelming sales of its debut commercial drug Monjuvi, MorphoSys has unveiled a new licensing deal with HIBio on two pipeline candidates which will help it focus on its key assets.

Monjuvi (tafasitamab-cxix) was launched by MorpoSys and partners Incyte as a second-line therapy for diffuse large B-cell lymphoma nearly two years ago, but has failed to live up to expectations,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Summit’s Ivonescimab Shows Significance On PFS, But Not Overall Survival

 
• By Joseph Haas

In a study intended to show similar benefit in western patients, PD-1/VEGF-targeting ivonescimab met a progression-free survival endpoint, but missed on OS.

Sanofi Bid For Second COPD Approval Hurt By Mixed Itepekimab Data

 
• By Kevin Grogan

One Phase III trial hits but a second study misses by a mile.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

More from Scrip

Quotables: Pharma Leaders On The Month’s Hot Topics

 
• By Anabel Costa-Ferreira

The highlights of recent comments and insights from industry executives on the key issues covered in Scrip.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

Astellas Gets CLDN.18.2-Targeted ADC From China’s Evopoint

 
• By Joseph Haas

Astellas will pay $130m up front for near-global rights to a Phase I/II antibody-drug conjugate that will add to its portfolio of CLDN.18.2-targeted drugs, including Vyloy.